<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1853">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361032</url>
  </required_header>
  <id_info>
    <org_study_id>ECC2020-06</org_study_id>
    <nct_id>NCT04361032</nct_id>
  </id_info>
  <brief_title>Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia</brief_title>
  <acronym>TRONCHER</acronym>
  <official_title>Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abderrahmane Mami Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eshmoun Clinical Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Datametrix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abderrahmane Mami Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with
      standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia.

      Multicentric, comparative, randomized study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arm1 :

        -  Usual standard treatment*

        -  Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion) a second injection may be
           considered if necessary, but no more than 800 mg per day. Only on the 1st day (D0)

        -  Enoxaparin (4000 IU X 2) per day for the duration of hospitalization

      VERSUS

      Arm 2:

        -  Usual standard treatment*

        -  Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution) by electric syringe
           40 mg/kg/day 5day/7 without exceeding 5 g per day for 14 days

        -  Enoxaparin (4000 IU X 2) per day for the duration of hospitalization

      Usual standard treatment*: according to the standard practices of each center, apart from the
      active molecules of the 2 arms and their therapeutic class)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 4, 2020</start_date>
  <completion_date type="Anticipated">October 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the mortality rate</measure>
    <time_frame>90 day</time_frame>
    <description>Evaluate the mortality rate at 90 days.
Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>COVID19</condition>
  <condition>Intensive Care Unit</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ROACTEMRA: (8mg/ kg per day) (1 injection per infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferoxamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DESFERAL: 500 mg, powder, and solvent for IV solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab Injection</intervention_name>
    <description>Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)</description>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>ROACTEMRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferoxamine</intervention_name>
    <description>Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)</description>
    <arm_group_label>Deferoxamine</arm_group_label>
    <other_name>DESFERAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient confirmed COVID19 positive

          -  Patient with acute respiratory deficiency

          -  Patient hospitalized in the intensive care unit

          -  Age &gt;18 years old

          -  Having given written consent for their participation in the study

        Exclusion Criteria:

          -  Taking Tocilizumab or hydroxychloroquine deferoxamine within one month prior to
             inclusion (excluding participation in THINC or COVID_2Pro or COVID+PA studies)

          -  Severe/severe liver failure

          -  Dialysis patients

          -  Renal insufficiency (clearance&lt; 30ml/min/1.73m2)

          -  Allergy to deferoxamine

          -  Pregnant or breastfeeding woman

          -  Hypersensitivity to the active substance or any of the excipients of Tocilizumab

          -  A decrease in blood platelets with previous use of enoxaparin or another heparin drug,

          -  hemophilia and related diseases,

          -  stomach or duodenal ulcer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eshmoun Clinical Research Centre</last_name>
    <phone>0021627870563</phone>
    <email>eshmouncompany@eshmoun.com.tn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chokri Jeribi, Dr</last_name>
    <phone>+21627870563</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eshmoun Clinical Research Centre/ HÃ´pital Abderrahmane Mami-Ariana</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <contact>
      <last_name>Chokri Jeribi, Dr</last_name>
      <phone>+21627870563</phone>
      <email>eshmouncompany@eshmoun.com.tn</email>
    </contact>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Abderrahmane Mami Hospital</investigator_affiliation>
    <investigator_full_name>Dr Jalila Ben Khelil</investigator_full_name>
    <investigator_title>Head of department</investigator_title>
  </responsible_party>
  <keyword>Deferoxamine</keyword>
  <keyword>Tocilizumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

